CN Bio, a leading organ-on-a-chip (OOC) company that designs and manufactures single- and multi-organ microphysiological systems (MPS), today announced the appointment of Joseph Parisi as US Director of Sales. In his new role, Joe will lead the expansion of the company’s sales and support activities for the US market to address the growing demand for new alternative methods (NAMs) in preclinical drug discovery.
Following a number of key senior appointments in the UK last year, Joe’s appointment will strengthen CN Bio’s growth in another key market – the US, providing a local source of expertise and support for customers looking to use the company’s Physiomimics.® OOC range of MPS. Over the past year, global demand for NAM has accelerated, particularly after the FDA Modernization Act 2.0 went into effect in the United States.1. Joe’s sales skills will be critical to meeting this growing demand; Working alongside the leadership team to drive commercial expansion strategies, while helping customers improve the human relevance of pre-clinical workflows and reduce animal model reliance.
Joe has a strong track record in delivering successful sales strategies across the biotechnology sector. He joins CN Bio from Phenomics (acquired by Bruker Corporation in 2023), where he was Director of Sales for US West and led an experienced sales team responsible for growing the proteomics side of the business. At Purigen Biosystems (acquired by Bionano Genomics in 2022), Joe was Director of West Coast Sales, where he oversaw commercial development, supporting the company’s growth from start-up to commercial success in three years. As part of this, he leads the development of internal commercial processes as well as a pre-launch sales plan, which helps accelerate initial sales and adoption. Additionally, he has held senior roles at numerous life sciences companies, including Isoplexis, Nanostring Technologies and Life Technologies. Joe holds a BSc in Molecular and Cellular Biology from the University of Illinois at Urbana-Champaign.
i amThe potential offered by CN Bio’s PhysioMimix range, evidenced by the company’s collaborative work with the FDA, is truly transformative for the drug discovery industry, providing clinical translatability that can improve efficacy and reduce drug failure. In my new role, I look forward to leveraging my experience within the sector to support the design and implementation of a commercial strategy that will enable us to meet the significant demand for animal model alternatives here in the United States.”
Joe Parisi, US Director of Sales, CN Bio
Dr. Paul Brooks, Chief Executive Officer, said: “It’s great to welcome Joe to the team. Throughout his career, he has repeatedly demonstrated his expertise in biotech sales, with a proven track record of success across companies at all stages of growth and commercialization. Joe’s appointment represents an important milestone in CN Bio’s growth, successfully building a strong international presence and now looking to expand into the US, a key market for innovative drug discovery.”